Poltreg Company Description

Poltreg S.A., a biotechnology company, researches and develops therapies for autoimmune diseases in Poland.

Its product pipeline includes PTG-OO7 + Rituximab which is in phase II clinical trial to treat presymptomatic T1D; MOG CAR-Treg which is in phase I clinical trial for the treatment of multiple sclerosis, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis; Multi-Edit/Allo MOG CAR-Treg which is in preclinical trial to treat multiple sclerosis, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis; and Antigen-specific T-regulatory cell (Tregs) which is in preclinical trial to treat T1D.

The company also develops CD6/CTLA4 CAR-Treg which is in phase I clinical trial to treat stage 3 T1D; CD6/CTLA4 CAR-Treg which is in preclinical trial for the treatment of vitiligo, atopic derm, psoriasis, and alopecia areata; CD6/CTLA4 CAR-Treg which is in preclinical trial to treat multiple sclerosis, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis; and PTG-OO7 + Rituximab which is in preclinical trial to treat presympt T1D.

In addition, it is developing cell therapies involve the use of human cells to regenerate a patient’s damaged tissues or organs.

The company was founded in 2015 and is headquartered in Gdansk, Poland.

Poltreg S.A.

Country	Poland
Founded	2015
Industry	Biotechnology
Sector	Healthcare
Employees	37
CEO	Piotr Trzonkowsk

Contact Details

Address: ul. Botaniczna 20 Gdansk, 80-298 Poland
Phone	48 512 532 401
Website	poltreg.bio

Stock Details

Ticker Symbol	PTG
Exchange	Warsaw Stock Exchange
Fiscal Year	January - December
Reporting Currency	PLN
ISIN Number	PLPLTRG00038
SIC Code	2836

Key Executives

Name	Position
Piotr Trzonkowsk	President of the Management Board
Paulina Kocenko-Merks	Chief Financial Officer and Member of Management Board
Mariusz Jablonski	Member of the Management Board
Kamilla Agnieszka Bok	Director of Operations